SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that it will present at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY.
Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will give a company overview on Thursday, Dec. 5, 2019 from 2:50 – 3:10 p.m. EST.
Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells’ chromosomes and can make many copies of themselves. ecDNA can be rapidly replicated within the cell, causing high numbers of oncogene copies, a trait that can be passed to daughter cells in asymmetric ways during cell division. Cells have the ability to upregulate or downregulate ecDNA and resulting oncogenes to ensure survival under selective pressures, including chemotherapy or radiation, making ecDNA one of cancer cells’ primary mechanisms of recurrence and treatment evasion. ecDNA are rarely seen in healthy cells but are found in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
About Boundless Bio
Boundless Bio is a biotechnology company committed to interrogating a previously unexplored dimension in cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers. For more information, visit www.boundlessbio.com.